A Phase 2 interventional study of COVID-19 Vaccine HIPRA and Cominarty (Pfizer-BioNtech) in SARS-CoV-2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 1 site in Vietnam. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Hipra Scientific, S.L.U · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in COVID-19 with a site in Vietnam — 4 open to participants now, 4 under way, 2 of them phase 3. COVID-19 · Vietnam.
Among the 30 studies in COVID-19 with a site in Vietnam, this one is the 10th largest by enrollment of the 23 interventional ones that give a count, is one of 13 that started in 2021, is one of 5 in phase 2, and was the 20th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →4 of the 30 studies in COVID-19 with a site in Vietnam are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Vietnam, United States, Argentina and 36 more countries
Ages 18+
Euresist Network GEIE · Sites in Vietnam, Germany, Italy and 3 more countries
Ages 18+
Euresist Network GEIE · Sites in Vietnam, Germany, Italy and 6 more countries
Ages 18+
University of Oxford · Sites in Vietnam, Belgium, Estonia and 13 more countries
Ages 0+
A study can be open while its sites in Vietnam have not opened yet or have stopped. Only those recruiting at a site in Vietnam →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 10 · Phase 4 1
First in 2020; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 629 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 573 across the 23 interventional studies, 807 across the 7 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Hipra Scientific, S.L.U is the lead sponsor of 8 studies on the registry; none are open to participants now.
Hipra Scientific, S.L.U has 8 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies in COVID-19 with a site in Vietnam that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in COVID-19 with a site in Vietnam, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam
The study population includes 256 healthy adults aged 18-60 which will be randomized in a ratio 1:1 test:commercial vaccine. Each participant will receive 2 immunisations separated by 21 days and will be followed for 24 weeks after the second dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.
Biological: COVID-19 Vaccine HIPRA
Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
Biological: Cominarty (Pfizer-BioNtech)
Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
Subjects will receive 2 injections of Cominarty administered 21 days apart
Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers
Number and percentage of solicited local and systemic reactogenicity adverse events for 7 days following each vaccination.
Time frame: 7 days
Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers
Number and percentage of unsolicited local and systemic reactogenicity adverse events for 28 days following each vaccination.
Time frame: 28 days
Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers
Change from baseline in safety laboratory parameters at 7 days following each vaccination.
Time frame: 7 days
Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers
Number and percentage of serious adverse events throughout the study duration.
Time frame: 30 weeks
Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers
Number and percentage of adverse events of special interest (AESI) throughout the study duration.
Time frame: 30 weeks
Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers
Number and percentage of medically attended adverse events (MAAE) related to study vaccine throughout the study duration.
Time frame: 30 weeks
Immunogenicity
Neutralization titer for each individual sample and GMT for group comparison at Day 21 and 35.
Time frame: Day 21 and 35.
Immunogenicity
IC50 of beta and delta variants.
Time frame: Day 21 and 35.
Immunogenicity
Geometric mean fold rise (GMFR) in neutralizing antibodies titers from baseline at Day 21 and 35.
Time frame: Day 21 and 35.
Immunogenicity at long-term
Neutralization titer for each individual sample and GMT for group comparison at 24 and 48 weeks after the second dose.
Time frame: 24 and 48 weeks after the second dose
Immunogenicity at long-term
IC50 of beta and delta variants.
Time frame: 24 weeks after the second dose
Immunogenicity at long-term
GMFR in neutralizing antibodies titers from baseline at 24 weeks after the second dose.
Time frame: 24 weeks after the second dose
Immunogenicity to the SARS-CoV-2 spike glycoprotein
Total binding antibody titer and GMT for group comparison at Day 21 and 35.
Time frame: Day 21 and 35
Immunogenicity to the SARS-CoV-2 spike glycoprotein
GMFR in total binding antibodies titer from baseline at Day 21 and 35.
Time frame: Day 21 and 35
Immunogenicity to the SARS-CoV-2 spike glycoprotein at long-term
Total Binding antibody titer and GMT for group comparison at 24 weeks after the second dose.
Time frame: 24 weeks after the second dose
Immunogenicity to the SARS-CoV-2 spike glycoprotein at long-term
GMFR in total binding antibodies titer from baseline at 24 weeks after the second dose.
Time frame: 24 weeks after the second dose
Immunogenicity to the SARS-CoV-2 spike glycoprotein
Percentage of subjects who seroconverted defined as a ≥4-fold change in total binding antibody titer from baseline at Day 21 and 35.
Time frame: Day 21 and 35.
Number of participants with symptomatic SARS-CoV-2 infections in participants without evidence of infection before COVID-19 HIPRA vaccination.
Number and percentage of subjects with symptomatic SARS-CoV-2 infections according to COVID-19 infection criteria.
Time frame: 30 weeks
Number of COVID-19 severe infections after receiving COVID-19 HIPRA vaccine.
Number and percentage of COVID-19 severe infections throughout the study duration.
Time frame: 30 weeks
Number of COVID-19 severe infections after receiving COVID-19 HIPRA vaccine.
Number and percentage of hospital admissions associated with COVID-19 throughout the study duration.
Time frame: 30 weeks
Number of COVID-19 severe infections after receiving COVID-19 HIPRA vaccine.
Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 throughout the study duration.
Time frame: 30 weeks
Number of COVID-19 severe infections after receiving COVID-19 HIPRA vaccine.
Number and percentage of deaths associated with COVID-19 throughout the study duration.
Time frame: 30 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2021 to primary completion in May 2022, 5 months.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 5 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2021 → May 2022, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HIPRA COVID-19 vaccine
Hipra Scientific, S.L.U